Merck Aims to Apply RNAi Expertise to microRNA Mimic Development
October 28, 2010
Merck Aims to Apply RNAi Expertise to microRNA Mimic Development
Merck is primarily focused on miRNA mimics since the molecules are "somewhat analogous" to siRNAs, which enables the company to piggyback on the know-how of its RNAi subsidiary Sirna Therapeutics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News - Merck Remains Committed to RNAi Despite Shuttering Its California Facility
August 4, 2011 / Gene Silencing News - Quark, Pfizer Amend Deal for Ocular Disease Drug on Less-than-Ideal Phase II Data
March 24, 2011 / Gene Silencing News - Alnylam, Max Planck Settle Suit Over Tuschl IP
March 17, 2011 / Gene Silencing News - Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
January 6, 2011 / Gene Silencing News